Antiviral drug development of hybridoma cell lines and antibody for viral antigens
Ended Purchase Order Awarded Last action
- Contract number
- 75N95023P00436
- Awardee
-
Sino Biological US Inc. UEI GVLNLKK92321
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $54,700
Award facts
- Opportunity
-
- Antiviral drug development of Hybridoma cell lines and antibody for viral antigens Solicitation · 75N95023Q00378 · Posted Jun 7, 2023
- Contract value 100% obligated
- $54,700.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Chesterbrook, PA, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$10,800 | |
| Original award | $65,500 |
About this award
This firm fixed-price purchase order for approximately $54,700 was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Sino Biological US Inc. to support antiviral drug development efforts. Under the contract, Sino Biological will generate hybridoma cell lines and monoclonal antibodies targeting four viral proteins of priority pathogens identified by the Antimicrobial Resistance Coordination and Strategy Unit. The work includes providing multiple positive clones and purified antibodies for each target, as well as validated antibody pairs if identified. This non-competitive award was issued utilizing the authority under FAR Part 13 for simplified acquisitions of commercial items, with performance taking place in Chesterbrook, Pennsylvania over a period of eight months.
Quick answers
Who was awarded contract 75N95023P00436?
75N95023P00436 was awarded to Sino Biological US Inc. by National Institute on Drug Abuse (National Institutes of Health) on July 21, 2023.
How much is contract 75N95023P00436 worth?
The government has obligated $54,700 on 75N95023P00436.
Which agency awarded contract 75N95023P00436?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95023P00436, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95023P00436 competed?
The extent of competition for 75N95023P00436 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award